Can buspirone be added as an adjunct to lurasidone (Latuda) in a patient taking lurasidone 80 mg daily who has persistent anxiety or agitation?

Can Buspirone Be Added to Lurasidone?

Yes, buspirone can be added as an adjunct to lurasidone for persistent anxiety or agitation, though the evidence supporting this specific combination is limited and indirect. This recommendation is based on the general safety profile of both medications and the lack of significant pharmacokinetic interactions, though no direct studies have evaluated this specific combination.

Rationale for Combination

Lurasidone's Anxiolytic Properties

Lurasidone itself demonstrates efficacy for anxiety symptoms in both schizophrenia and bipolar depression. In patients with schizophrenia and moderate-to-severe anxiety (PANSS G2 score ≥4), both 40 mg and 80 mg doses significantly reduced anxiety symptoms from weeks 2-6 compared to placebo 1. Similarly, in bipolar depression, lurasidone significantly reduced both psychic anxiety (HAM-A items 1-6,14) and somatic anxiety (items 7-13) symptoms 2. Before adding buspirone, ensure the patient is on an adequate dose of lurasidone (at least 80 mg daily with food) for sufficient duration (4-6 weeks).

When to Consider Buspirone Augmentation

If anxiety or agitation persists despite optimized lurasidone therapy, buspirone may be considered based on:

• Mechanism: Buspirone acts as a 5-HT1A partial agonist, providing a different mechanism than lurasidone's dopamine D2/serotonin 5-HT2A antagonism
• Safety profile: Buspirone is classified as a non-benzodiazepine anxiolytic with lower risk of tolerance, addiction, depression, and cognitive impairment compared to benzodiazepines 3
• Onset consideration: Buspirone requires 2-4 weeks to become effective and is useful only for mild-to-moderate agitation 3

Dosing Strategy

Start buspirone at 5 mg twice daily and titrate to a maximum of 20 mg three times daily (60 mg/day total) 3. Increase the dose in 5 mg increments every 5-7 days based on response and tolerability.

Evidence for Buspirone Augmentation

While no studies specifically examine buspirone added to lurasidone, evidence from depression treatment provides relevant guidance. In patients with major depression inadequately responsive to SSRIs, buspirone augmentation produced complete or partial remission in 59% of patients, with 79% of responders maintaining improvement at 4-month follow-up 4.

In the STAR*D trial comparing augmentation strategies for treatment-resistant depression, buspirone augmentation of citalopram showed similar response and remission rates to bupropion augmentation, though bupropion demonstrated greater reduction in depression severity 5. Importantly, discontinuation due to adverse events was lower with bupropion than buspirone 5.

Safety Considerations

Drug Interactions

There are no significant pharmacokinetic interactions between buspirone and lurasidone. However, monitor for:

• Serotonin syndrome risk: While lurasidone is not primarily serotonergic, combining multiple agents affecting serotonin requires vigilance. Start buspirone at low doses and monitor for mental status changes, neuromuscular hyperactivity, and autonomic instability, especially in the first 24-48 hours after dose changes 6
• Additive sedation: Both medications can cause somnolence. Lurasidone causes somnolence in 11-17% of patients 7, and buspirone may contribute additional sedation

Common Pitfalls

• Expecting immediate results: Counsel patients that buspirone requires 2-4 weeks for anxiolytic effects 3
• Inadequate lurasidone dosing: Ensure lurasidone is taken with food (≥350 calories) to achieve adequate absorption 7
• Premature discontinuation: Buspirone's delayed onset may lead to premature abandonment of therapy

Alternative Considerations

For acute agitation requiring immediate intervention, benzodiazepines (lorazepam 0.5-1 mg) are more appropriate 8, 9. However, benzodiazepines carry risks of tolerance, addiction, cognitive impairment, and paradoxical agitation in ~10% of patients 3.

For severe, persistent agitation unresponsive to lurasidone optimization, consider:

• Dose optimization of lurasidone up to 120-160 mg daily (higher doses show greater efficacy for agitation in schizophrenia) 10
• Mood stabilizers like divalproex sodium (better tolerated than carbamazepine) 3
• Switching to or augmenting with clozapine in treatment-resistant cases

Monitoring Plan

After initiating buspirone:

• Assess anxiety symptoms weekly for the first month using standardized scales
• Monitor for serotonin syndrome symptoms, particularly during dose titration
• Evaluate for excessive sedation or cognitive impairment
• Reassess need for continuation after 9 months of stable response 3